Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Very often patients receive medications before a diagnostic, therapeutic, or surgical procedure to help them relax, keep them calm, and to relieve them from pain. This is called procedural sedation. With respect to minimal-to-moderate procedural sedation for minor surgical procedures, a patient is first given a pain-relief medication (analgesic) and then a medication to help him/her relax and keep calm (sedative). AQUAVAN is a chemically modified form of propofol, a commonly-used sedative drug. AQUAVAN acts like a slow release version of propofol, and is being studied to see if it can safely keep patients calm and relaxed during their medical procedure and then allow for rapid and clear-headed recovery.
This is a Phase 3 open-label, single-arm study designed to evaluate the safety of AQUAVAN following pretreatment with an analgesic, fentanyl, in patients who are undergoing minor surgical procedures that require minimal-to-moderate sedation. All patients will be placed on supplemental oxygen via nasal cannula and an electrocardiogram monitor, pulse oximeter, and blood pressure monitor will be attached prior to administration of fentanyl. Assessments will be made to evaluate the safety of AQUAVAN in patients undergoing minor surgical procedures.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AQUAVAN® (fospropofol disodium) Injection | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Airway Assistance in Patients Undergoing Minor Surgical Procedures | 2 hours |
Not provided
Not provided
- Number of sites/patients: Approximately 18 sites and 125 patients.
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| James B Jones, MD, PharmD | Eisai Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Precision Trials | Phoenix | Arizona | 85032 | United States | ||
| Borland-Groover Clinic |
All subjects received fentanyl at an initial dose of 50 μg as an analgesic pretreatment 5 minutes prior to the administration of the initial dose of fospropofol disodium (also referred to as LUSEDRA and formerly known as AQUAVAN). After fentanyl administration, the venous catheter was flushed with 2 mL of sterile saline solution.
This study recruited at 12 study centers in the US during the period of 22-Jun-2006 to 01 Mar 2007.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Fospropofol Disodium | Fospropofol disodium 6.5 mg/kg (no less than 390 mg and no more than 585 mg, based on age, weight, and American Society of Anesthesiologists [ASA] Status): one initial intravenous (i.v.) bolus dose. Supplemental doses of fospropofol disodium 1.63 mg/kg (no less than 97.5 mg and no more than 146 mg) were administered as needed. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Jacksonville |
| Florida |
| 32256 |
| United States |
| University of Louisville | Louisville | Kentucky | 40202 | United States |
| Medical Research Institute, Inc. | Slidell | Louisiana | 70458 | United States |
| Medical Research Institute | Slidell | Louisiana | 70458 | United States |
| Chevy Chase Clinical Research | Chevy Chase | Maryland | 20815 | United States |
| Chesapeake Research Group, LLC | Pasadena | Maryland | 21122 | United States |
| St. Louis Women's Healthcare Group | Chesterfield | Missouri | 63017 | United States |
| International Heart Institute of Montana | Missoula | Montana | 59802 | United States |
| Hudson Valley Urology, PC | Poughkeepsie | New York | 12601 | United States |
| Duke University Medical Center | Durham | North Carolina | 27710 | United States |
| Southern Orthopaedic Sports Medicine | Columbia | South Carolina | 29204 | United States |
| Carolina Urologic Research | Myrtle Beach | South Carolina | 29572 | United States |
| Dallas VA Medical Center | Dallas | Texas | 75216 | United States |
| Physicians' Research Options | Sandy City | Utah | 84070 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Fospropofol Disodium | Fospropofol disodium 6.5 mg/kg (no less than 390 mg and no more than 585 mg, based on age, weight, and American Society of Anesthesiologists [ASA] Status): one initial intravenous (i.v.) bolus dose. Supplemental doses of fospropofol disodium 1.63 mg/kg (no less than 97.5 mg and no more than 146 mg) were administered as needed. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race/Ethnicity, Customized | Number | particpants |
| |||||||||||||||||||||||
| Weight (kg) | Number | participants |
| |||||||||||||||||||||||
| American Society of Anesthesiologists (ASA) status | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Incidence of Airway Assistance in Patients Undergoing Minor Surgical Procedures | Number of patients requiring specified types of airway assistance | Posted | Number | particpants | 2 hours |
|
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Fospropofol Disodium | Fospropofol disodium 6.5 mg/kg (no less than 390 mg and no more than 585 mg, based on age, weight, and American Society of Anesthesiologists [ASA] Status): one initial intravenous (i.v.) bolus dose. Supplemental doses of fospropofol disodium 1.63 mg/kg (no less than 97.5 mg and no more than 146 mg) were administered as needed. | 4 | 123 | 111 | 123 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cardiac arrest | Cardiac disorders |
| |||
| Atrial septal defect | Congenital, familial and genetic disorders |
| |||
| Ammonia increased | Investigations |
| |||
| Hepatic encephalopathy | Nervous system disorders |
| |||
| Apnoea | Respiratory, thoracic and mediastinal disorders |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Constipation | Gastrointestinal disorders |
| |||
| Nausea | Gastrointestinal disorders |
| |||
| Vomiting | Gastrointestinal disorders |
| |||
| Procedural pain | Injury, poisoning and procedural complications |
| |||
| Dizziness | Nervous system disorders |
| |||
| Headache | Nervous system disorders |
| |||
| Paresthesia | Nervous system disorders |
| |||
| Tremor | Nervous system disorders |
| |||
| Uterine spasm | Reproductive system and breast disorders |
| |||
| Nasal discomfort | Respiratory, thoracic and mediastinal disorders |
| |||
| Pharyngolaryngeal pain | Respiratory, thoracic and mediastinal disorders |
| |||
| Pruritus | Skin and subcutaneous tissue disorders |
| |||
| Hypotension | Vascular disorders |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Eisai Medical Services | Eisai Inc | 1-888-422-4743 |
| ID | Term |
|---|---|
| D001164 | Arteriovenous Fistula |
| D000071378 | Bunion |
| D004108 | Dilatation, Pathologic |
| ID | Term |
|---|---|
| D001165 | Arteriovenous Malformations |
| D054079 | Vascular Malformations |
| D018376 | Cardiovascular Abnormalities |
| D002318 | Cardiovascular Diseases |
| D016157 | Vascular Fistula |
| D014652 | Vascular Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D005402 | Fistula |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D005531 | Foot Deformities, Acquired |
| D005530 | Foot Deformities |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C472965 | fospropofol |
| D007267 | Injections |
| ID | Term |
|---|---|
| D004333 | Drug Administration Routes |
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Hispanic/Latino |
|
| Other |
|
| >90 |
|
| P3 ( A patient with severe systemic disease ) |
|
| P4 (High risk, severely compromised by disease) |
|
| Title | Measurements |
|---|---|
|
| Chin Lift |
|
| Oral Airway |
|
| Increased Oxgen Flow |
|